QCG
ORGO icon

Quadrant Capital Group’s Organogenesis Holdings ORGO Stock Holding History

Quadrant Capital Group’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,538
Closed -$3.28K – 2745
2023
Q1 		$3.28K Buy
1,538
+292
+23% +$721 ﹤0.01% 2322
2022
Q4 		$3.35K Buy
1,246
+493
+65% +$1.44K ﹤0.01% 2297
2022
Q3 		$2K Buy
+753
New +$3.4K ﹤0.01% 2404

Other funds holding ORGO

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's ORGO Position: Q2 2023 in Review

Quadrant Capital Group sold out of Organogenesis Holdings (ORGO) in Q2 2023, closing a stake of 1,538 shares — an estimated $3.28K sold.

Quadrant Capital Group first reported a position in ORGO in Q3 2022 and held it in 3 quarters. The position peaked at $3.35K in Q4 2022. 113 funds tracked by Wall St. Rank hold ORGO as of Q2 2023.

  • Quadrant Capital Group reported no remaining Organogenesis Holdings position as of Q2 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 1,538 Organogenesis Holdings shares in Q2 2023, an estimated $3.28K.
  • Quadrant Capital Group first reported a position in Organogenesis Holdings in Q3 2022 and held it in 3 quarters.
  • Quadrant Capital Group's Organogenesis Holdings position peaked at $3.35K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.